Adenosine Unlocks How Ketamine and ECT Fight Treatment-Resistant Depression
A landmark Nature study reveals adenosine surges in the prefrontal cortex as the shared mechanism behind ketamine and ECT antidepressant effects.
Summary
Researchers at Chinese brain research institutes used genetically encoded adenosine sensors to show that both ketamine and electroconvulsive therapy (ECT) rapidly elevate extracellular adenosine in the medial prefrontal cortex and hippocampus of mice. Blocking A1 and A2A adenosine receptors abolished antidepressant effects, while activating them mimicked therapy. Ketamine boosts adenosine through cellular metabolic shifts, not neuronal hyperactivity. Based on this, novel ketamine derivatives were developed with stronger adenosine-boosting properties, better antidepressant efficacy, and fewer side effects. Strikingly, acute intermittent hypoxia—a non-drug approach—replicated these effects by also raising brain adenosine, suggesting scalable non-pharmacological treatment paths.
Detailed Summary
Major depressive disorder affects hundreds of millions globally, and roughly one-third of patients fail to respond to standard antidepressants. Ketamine and ECT offer rapid relief in treatment-resistant cases, often within hours, but their precise mechanisms have remained poorly understood—limiting the ability to refine or replicate their benefits.
This study, published in Nature, deployed GPCR-based fluorescent adenosine sensors (GRABAdo1.0) combined with multichannel fibre photometry and two-photon imaging to monitor extracellular adenosine dynamics in real time across multiple brain regions in freely behaving mice. Both a single subanaesthetic dose of ketamine (10 mg/kg i.p.) and ECT triggered rapid, robust adenosine surges specifically in the medial prefrontal cortex (mPFC—including prelimbic, infralimbic, and anterior cingulate subregions) and hippocampus, but not in the nucleus accumbens. These surges peaked within ~500 seconds, were dose-dependent for ketamine, and were reproduced in chronic restraint stress depression models.
Genetic knockout or pharmacological blockade of both A1 (Adora1) and A2A (Adora2a) adenosine receptors completely eliminated the antidepressant behavioral effects of ketamine and ECT. Conversely, direct activation of these receptors—particularly within the mPFC—was sufficient to produce antidepressant-like effects in mice, establishing adenosine signaling as causally necessary and sufficient. The mechanism by which ketamine elevates adenosine was traced to modulation of intracellular metabolism, increasing intracellular adenosine levels and subsequent extracellular release, without inducing neuronal hyperactivity. Notably, ketamine's primary metabolites (norketamine and HNK) did not trigger adenosine surges, implicating the parent compound directly.
Leveraging this mechanistic insight, the team synthesized ketamine derivatives engineered to amplify adenosine signaling. These compounds demonstrated enhanced antidepressant efficacy at therapeutic doses while displaying a reduced side-effect profile compared to ketamine. Additionally, acute intermittent hypoxia—controlled, brief reductions in inspired oxygen—elevated brain adenosine and produced antidepressant effects in mice that were blocked by adenosine receptor antagonists, paralleling ketamine and ECT. This establishes a non-pharmacological, scalable adenosine-boosting strategy.
The findings reframe adenosine signaling—particularly in the mPFC—as the unifying molecular hub of rapid-acting antidepressants, opening a tractable target for next-generation therapies with improved safety and accessibility.
Key Findings
- Ketamine and ECT both induce rapid adenosine surges in the mPFC and hippocampus of mice.
- Blocking A1 and A2A adenosine receptors completely abolishes antidepressant effects of both treatments.
- Ketamine boosts adenosine via metabolic modulation, not neuronal hyperactivity; metabolites are inactive.
- Novel ketamine derivatives that enhance adenosine signaling show better efficacy and fewer side effects.
- Acute intermittent hypoxia raises brain adenosine and produces adenosine-dependent antidepressant effects.
Methodology
Mouse models (naive and chronic restraint stress) were used alongside GRABAdo1.0 genetically encoded adenosine sensors monitored via fibre photometry and two-photon imaging. Genetic knockouts, pharmacological receptor blockade/activation, and chemogenetic tools were combined with behavioral depression assays; novel ketamine derivatives were tested for efficacy and side-effect profiles.
Study Limitations
All mechanistic experiments were conducted in mice, requiring validation in human subjects and clinical ECT contexts. The complexity of spatiotemporal adenosine regulation—including potential adverse effects of chronic A2A activation in certain regions—was acknowledged but not fully resolved. The novel ketamine derivatives have not yet been tested in humans.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.